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ABSTRACT
Reinfections with SARS-CoV-2 have already been documented in humans, although its real incidence is currently
unknown. Besides having a great impact on public health, this phenomenon raises the question of immunity
generated by a single infection is sufficient to provide sterilizing/protective immunity to a subsequent SARS-CoV-2
re-exposure. The Golden Syrian hamster is a manageable animal model to explore immunological mechanisms able
to counteract COVID-19, as it recapitulates pathological aspects of mild to moderately affected patients. Here, we
report that SARS-CoV-2-inoculated hamsters resolve infection in the upper and lower respiratory tracts within seven
days upon inoculation with the Cat01 (G614) SARS-CoV-2 isolate. Three weeks after the primary challenge, and
despite high titres of neutralizing antibodies, half of the animals were susceptible to reinfection by both identical
(Cat01, G614) and variant (WA/1, D614) SARS-CoV-2 isolates. However, upon re-inoculation, only nasal tissues were
transiently infected with much lower viral replication than those observed after the first inoculation. These data
indicate that a primary SARS-CoV-2 infection is not sufficient to elicit a sterilizing immunity in hamster models but
protects against lung disease.
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Introduction
The Severe Acute Respiratory Syndrome Coronavirus
2 (SARS-CoV-2) is the etiological agent of Corona-
virus Infectious Disease 2019 (COVID-19), a
respiratory affection that spread globally with an
unprecedented rapidity and severity, impacting
both international public health and economics. To
date, SARS-CoV-2 has infected more than 84 million
people globally, resulting in more than 1.8 million
deaths, as reported by the World Health Organiz-
ation [1].
Unravelling immunopathological disorders caused
by SARS-CoV-2 are one of the priorities of the scien-
tific community. SARS-CoV-2 infection induces a
rapid production of neutralizing antibodies [2]; how-
ever, the magnitude of a neutralizing response, as
well as its decay, correlates directly with the severity
of the disease. To date, longitudinal studies
confirmed the duration of neutralizing antibodies
for 2–5 months post-symptoms onset [3–5] In
addition, the degree of protection against a reinfec-
tion event caused by identical or other viral variants
is still not clear. The first evidence of COVID-19
reinfection was described by 25 August 2020 [6].
This study reported reinfection of an individual
142 days after the first infectious episode. The patient
did not display any symptom during the second
infection; viruses belonging to different SARS-CoV-
2 clades were identified from the first and second
episodes. Immediately after this first case, other
SARS-CoV-2 reinfections have been reported in sev-
eral countries, including The Netherlands, Belgium,
Spain, Sweden, Qatar, South Korea, United States,
Ecuador, and India [7–11] The symptoms described
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in these cases had different degrees of severity com-
pared to the first infectious event and ranged from
asymptomatic to severe disease, being more intense
during the second infections in few patients. In all
cases, differences in viral genomic sequences were
identified between the first and second infections.
Experimental reinfection studies have been per-
formed in non-human primates (NHPs), transgenic
mice expressing the human angiotensin-converting
enzyme 2 (hACE2), Cyclophosphamide (CyP)
immunosuppressed and RAG2-knockout Golden
Syrian hamster (Mesocricetus auratus) and cat (Felis
catus) [12–16] In all models, animals re-challenged
with the same SARS-CoV-2 isolate developed a pro-
tective non-sterilizing immunity. Currently, there is
no data available about the induction of protective
immunity conferred by a given strain versus another
variant.
The golden Syrian hamster is a suitable model to
study COVID-19 [17,18]. SARS-CoV-2 can replicate
on both upper and lower respiratory tracts in this
animal model. Upon challenge, animals develop a
mild-to-moderate disease with a recovery period ran-
ging from one to two weeks. Importantly, infection
with SARS-CoV-2 in hamsters recapitulates several
lesions observed in the human lower respiratory
tract. These include pneumonia with bilateral lungs
involvement, ground-glass opacities, presence of
focal oedema, inflammation, and acute respiratory
distress syndrome [19]. To date, excluding hamsters,
only NHPs partially reproduce the clinical picture
experienced by COVID-19 human patients. In
addition, age and sex-linked differences in SARS-
CoV-2 infection and clinical signs have been
reported in hamsters, reflecting human similarities
[17,20]. Thus, the golden Syrian hamster could be
an appropriate model to study SARS-CoV-2
reinfections.
Here, we test the capacity of SARS-CoV-2 to rein-
fect golden Syrian hamsters using two variants of the
virus: Cat01, a variant isolated from a human patient
in Spain and WA/1 a variant isolated from a human
patient in the USA. The Cat01 isolate differs from
the WA/1 one by the presence of 15 single point
mutations. Among them, the most striking is at
the 614 position of the Spike protein gene; the
WA/1 isolate possesses a wild-type D614 spike
protein, while the Cat01 isolate displays the G614
mutation. S-G614 strains emerged for the first time
in Europe during March 2020 and quickly spread
globally, arriving almost at fixation and replacing
S-D614 variants [21]. Further studies demonstrated
that D614G variants have a higher transmission
capacity [22–24] and reach higher viral loads in
the upper airways [25]. It is, therefore, important
to gain insights into mechanisms of reinfection
and the development of protective immunity using
different viral strain, which could interfere with a
primary infection event.
Our results demonstrate that animals exposed to
the Cat01 variant developed a cross-protective but
not sterilizing immune response against a second
infection event, regardless of the viral variant used
for the re-challenge. Importantly, we showed that
identical and variant viral strains could successfully
infect the upper respiratory tract of re-challenged ani-




Animal experiments were approved by the Insti-
tutional Animal Welfare Committee of the Institut
de Recerca i Tecnologia Agroalimentàries (CEEA-
IRTA, registration number CEEA 188/2020) and by
the Ethical Commission of Animal Experimentation
of the Autonomous Government of Catalonia (regis-
tration number FUE-2020-01589810) and conducted
by certified staff. Experiments with SARS-CoV-2
were performed at the Biosafety Level-3 (BSL-3) facili-
ties of the Biocontainment Unit of IRTA-CReSA (Bar-
celona, Spain).
Virus isolates
Two different SARS-CoV-2 isolates were used:
hCoV-19/Spain/CT-2020030095/2020 (GISAID ID
EPI_ISL_510689), designated as Cat01, and hCoV-
19/USA/WA1/2020 (GISAID ID EPI_ISL_404895),
designated as WA/1. The WA/1 isolate was
kindly provided by Dr Slobodan Paessler (University
of Texas, USA). Cat01 was isolated from human
patient (Oropharyngeal swab) from Spain in March
2020.
Compared to Wuhan/Hu-1/2019 strain, Cat01
isolate has the following point mutations: D614G
(Spike), R682L (Spike), C16X (NSP13) and other
12 in NSP3 (M1376X, P1377X, T1378X, T1379X,
I1380X, A1381X, K1382X, N1383X, T1384X,
V1385X, K1386X, S1387X). SARS-CoV-2 WA1 was
isolated from a human patient (Oropharyngeal
swab) from Washington State (US) in January
2020 and differs from the Wuhan/Hu-1/2019 strain
for the presence of a single point mutation: L84S
(NS8).
Production of virus stocks (Cat01 passage number
3; WA/1 passage number 2), isolation, titration and
live virus neutralization assay were performed in
Vero E6 cell (ATCC® CRL-1586™). Virus titres
were determined using a standard TCID50 assay
and expressed as TCID50 /mL. Viral stock used for
the experimental infection is the same used that
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have been sequenced and submitted in the GISAID
public repository (GISAID ID EPI_ISL_510689).
Study design
A total of thirty-four 5-6-week-old male and female
golden Syrian hamsters (Charles River) were used in
this study (Figure 1). Under isoflurane anaesthesia,
24 hamsters were inoculated by intranasal instillation
with 105.8 TCID50 of the SARS-CoV-2 Cat01 isolate
per animal (100 µL/individual, 50 µL for each nostril).
Ten hamsters were mock intranasally inoculated with
PBS (100 µL/individual, 50 µL for each nostril) and
used as negative controls. Body weight was monitored
daily during the first-week post-inoculation and 4 days
post-re-inoculation. For virological and pathological
examinations, 4 inoculated and 2 control hamsters
(half male and half female) were sacrificed on days
2, 4, and 7 dpi. The weight of remaining hamsters
(n = 12 inoculated and n = 4 control) was recorded at
10, 14, and 21 dpi.
At 21 dpi, 6 animals from the inoculated group
were intranasally re-inoculated with 105.2 TCID50
of SARS-CoV-2 Cat01 isolate (100 µL/individual,
50 µL for each nostril), while the other six animals
received the same dose of the WA1 isolate. The
four control hamsters were re-inoculated with the
same amount of PBS serving as negative controls
of the re-inoculation. Inoculation procedures were
the same as those used for the first part of the
experiment. For virological and pathological exam-
inations, 3 inoculated animals for each viral isolate
and 2 control animals were sacrificed at 23 dpi
(2 dpri) and 25 dpi (4 dpri).
At necropsy, samples from nasal turbinate, trachea
and lung were taken and fixed by immersion in 10%
buffered formalin. For molecular detection and viral
titration purposes, a portion of the same tissues was
placed in individual Eppendorf tubes containing
500 µL of DMEM (GIBCO) supplemented with 1%
penicillin–streptomycin (PS) (GIBCO) with a single
zinc-plated, steel, 4.5-mm bead. Samples were hom-
ogenized at 30 Hz for 2 min using a TissueLyser II
(QIAGEN GmbH, Hilden, Germany) and centrifuged
for 30 s at 11,000 rpm. All samples were stored at −70°
C. Blood samples were collected from each animal at
the necropsy day by cardiac puncture under deep
anesthesia, centrifugated 10 min at 2100 rpm at RT
Figure 1. Experimental design. Golden Syrian hamsters (n = 24, 12 male and 12 female) were intranasally (IN) inoculated with
105.8 TCID50 of SARS-CoV-2 Cat01 isolate. Before the challenge blood samples and oropharyngeal swabs (OS) were collected
from all animals. At 2-, 4- and 7-days post-inoculation (dpi), 4 infected animals (2 male and 2 female) were euthanized. Before
necropsy, blood samples and OS were collected from each animal. Nasal turbinate, lungs and trachea were collected for patho-
logical and virological analyses. In purple, samples used for ELISA and seroneutralization test; in green, samples used for histo-
pathology and immunohistochemistry; in yellow, samples used for RT-qPCR and viral titration in Vero E6 cell. At 21 dpi, the
remaining animals (n = 12) were equally divided into two experimental groups. One group was intranasally inoculated with
105.2 TCID50 of Cat01 isolate while the other was IN inoculated with WA/1 strain at the same concentration. At day 23-dpi (2
days-post re-inoculation) and 25-dpi (4 days-post re-inoculation), 3 animals/experimental group were euthanized. Sampling
was equivalent to that indicated previously. Created with BioRender.com
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and stored at −70°C for further analysis. Similarly,
oropharyngeal and rectal swabs were collected before
the sacrifice under deep anaesthesia, resuspended in
500 µL of DMEM supplemented with 1% PS and
stored at −70°C for further analysis. Clinical evol-
ution, as well as pathological, immunological and vir-
ological outcomes, were evaluated at different time
points as indicated in Figure 5.
Pathology and immunohistochemistry
Upper (nasal turbinate) and lower (trachea and lung)
respiratory tract formalin-fixed samples were routi-
nely processed for histopathology and hematoxyli-
n&eosin stained slides examined under an optical
microscope. The mediastinal lymph node was also
studied in 13 out of the 34 analysed animals, since
not in all cases was identified while taking samples
during necropsy or during the trimming of tissues.
A semi-quantitative approach based on the amount
of inflammation (none, mild, moderate, or severe)
was used to score the damage caused by SARS-CoV-
2 infection in hamsters.
A previously described immunohistochemistry
technique to detect SARS-CoV-2 NP antigen [26]
using the rabbit monoclonal antibody (40143-R019,
Sino Biological, Beijing, China) at dilution 1:1000,
was applied on nasal turbinates, trachea, lung and
mediastinal lymph nodes. The amount of viral antigen
in tissues was semi-quantitatively scored in the differ-
ent studied tissues (low, moderate, and high amount,
or lack of antigen detection).
RNA-extraction and quantitative RT–PCR
Viral RNA was extracted from target organs and
swabs samples using the IndiMag pathogen kit (Indi-
cal Bioscience) on a Biosprint 96 workstation (QIA-
GEN) according to the manufacturer’s instructions.
RT–PCR used to detect viral gRNA is based on the
one published by Corman et al. [27], with minor
modification to adapt it to the AgPath-ID One-
Step RT–PCR Kit (Life Technologies). RT–PCR tar-
gets a portion of the envelope protein gene (position
26,141–26,253 of GenBank NC_004718). The pri-
mers and probes used, and their final concentration
are the follow: forward: 5′-ACAGGTACGTTAA-
TAGTTAATAGCGT-3′ [400 nM], reverse: 5′-
ATATTGCAGCAGTACGCACACA-3′ [400 nM]
probe: 5′-FAM-ACACTAGCCATCCTTA CTGCGC
TTCG-TAMRA-3′ [200 nM]. Thermal cycling was
performed at 55°C for 10 min for reverse transcrip-
tion, followed by 95°C for 3 min and then 45 cycles
of 94°C for 15 s, 58°C for 30 s. sgRNA detection by
RT–PCR is based on protocol published by Wölfel
et al. [28] with minor modification to adapt it to
the AgPath-ID One-Step RT–PCR Kit. The primers
and probes are the same used for gRNA detection
except for primer forward: 5′-CGATCTCTTGTA-
GATCTGTTCTC-3′. [400 nM]. Thermal cycling
was performed at 55°C for 10 min for reverse tran-
scription, followed by 95°C for 3 min and then 45
cycles of 95°C for 15 s, 56°C for 30 s.
Viral titration in Vero E6 cell
Supernatant from the homogenized trachea, lungs,
nasal turbinates OS samples and resuspended OS
samples collected at different times after (re)
inoculation were evaluated for infectious virus by
titration in Vero E6 cells as previously described
[29, 30]. Briefly, each sample was 10-fold diluted
(10−1–10−7) in duplicate, transferred in a 96 well
plate with a Vero E6 cells monolayer and incu-
bated at 37°C and 5% CO2. Plates were daily mon-
itored under the light microscope and wells were
evaluated for the presence of CPE at 5 dpi. The
amount of infectious virus was calculated by deter-
mining the TCID50 using the Reed–Muench
method.
Evaluation of the humoral response against
SARS-CoV-2 by ELISA
The level of anti-SARS-CoV-2 antibodies in hamster
serum samples was determined using a sandwich-
ELISA. Nunc MaxiSorp ELISA plates were coated
overnight at 4°C with 50 μL of capture antibody
(anti-6xHis antibody, clone HIS.H8; ThermoFisher
Scientific) at 2 μg/mL in PBS. Then, plates were
blocked for 2 h at room temperature using PBS/1%
of bovine serum albumin (BSA) (Miltenyi biotech)
and 50 μL (1 μg/mL in blocking buffer) of the
SARS-CoV-2 Spike (S1+S2), receptor-binding
domain (RBD) or nucleocapsid protein (NP) (Sino
Biologicals, Beijing, China) was added and incubated
overnight at 4°C. Each sample was diluted in a block-
ing buffer and assayed in duplicated. Diluted samples
were incubated overnight at 4°C. Antigen free wells
were also assayed in parallel in the same plate to
evaluate sample background. Serial dilutions of a
positive serum sample were used as standard. As a
secondary antibody, an HRP-conjugated Goat anti-
hamster IgG (H + L) (Jackson Immunoresearch) at
1/20,000 dilution in blocking buffer was used. Sec-
ondary antibody was incubated for one hour at
room temperature. Plates were revealed using o-Phe-
nylenediamine dihydrochloride (OPD) (Sigma
Aldrich) and stopped with 4N of H2SO4 (Sigma
Aldrich). The signal was analysed as the optical den-
sity (OD) at 492 nm with noise correction at 620 nm.
The specific signal for each antigen was calculated
after subtracting the background signal obtained for
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each sample in antigen-free wells. Results are shown
as arbitrary units (AU).
Live virus neutralization assay
Prior neutralization assay, sera samples were heat
inactivated at 56°C for 30 min. Inactivated sera
samples were serially 2-fold diluted (range 1/40–1/
20,480) in DMEM supplemented with 100 U/mL peni-
cillin, 100 µg/mL streptomycin, and 2 mM glutamine
(all ThermoFisher Scientific), mixed with SARS-
CoV-2 Cat01 or WA/1 isolates and further incubated
at 37°C for 1 h. Each dilution (in duplicates) contain-
ing 100 TCID of virus solution. The mixtures were
then transferred to Vero E6 cell monolayers (ATCC
CRL-1586) and cultured for three days at 37°C and
5% CO2. Cytopathic effects of the virus were measured
after three days using the CellTiter-Glo luminescent
cell viability assay (Promega), according to the manu-
facturer’s protocol. Luminescence was measured in a
Fluoroskan Ascent FL luminometer (ThermoFisher
Scientific).
Statistical analysis
Statistical analyses were completed using GraphPad
Prism 8. Mean weight data were analysed using a
Mixed-effect model (REML) with Dunnett’s multiple
comparisons test. The normality of each data set for
gRNA, sgRNA and infection viral loads was calculated
using Shapiro–Wilk test. Comparison of viral loads
between primary challenge and rechallenge was per-
formed with ordinary one-way ANOVA and Dun-
nett’s multiple comparisons (paired test) or Kruskal–
Wallis and Dunn’s multiple comparison test (unpaired
test). In all analyses, a P value <.05 was considered
statistically significant.
Results
Hamsters do not lose weight after SARS-CoV-2
reinfection
The level of protection conferred by prior inoculation
of SARS-CoV-2 was explored. Weight loss was used
to clinically track infection and reinfection [14]
(Figure 2). Hamsters inoculated for the first time
with 105.8 TCID50/animal of SARS-CoV-2 isolate
Cat01 (n = 24) showed a progressive reduction of
weight starting from 1 until 5 day post infection (dpi)
compared to the mock-inoculated animals (Figure 2
(a)), according to what has been previously described
[12,18]. The maximum mean weight loss for infected
animals was –3.56% (SD ± 4.34%; n = 16) at 5 dpi.
From 6 dpi onwards, animals recovered weight in a
similar trend to that of the control group, indicating
the beginning of the clinical recovery. Mean weight
differences between SARS-CoV-2 and mock-infected
animals were statistically significant starting from
2 dpi. On day 21 after inoculation, twelve animals
that underwent a primary SARS-CoV-2 infection
with the Cat01 isolate were re-challenged with Cat01
(n = 6) orWA/1 (n = 6) isolates, at a final concentration
of 105.2 TCID50/animal. Upon reinfection with both
variants, animals did not have statistically significant
weight variations compared to the control group
(Figure 2(b)).
SARS-CoV-2 causes rhinitis and
bronchointersticial pneumonia upon infection
but minimal to no lesions upon reinfection
Moderate to severe inflammatory lesions were
observed in nasal turbinates at 2 and 4 dpi, being
mild at 7 dpi. Animals developed multifocal to
diffuse, muco-purulent to non-suppurative rhinitis,
which was more evident in the mid and caudal turbi-
nates. Epithelial cell cilia loss was observed
Figure 2.Weight variation upon first inoculation and re-challenge. Data are expressed as a percentage of variation referred to the
weight recorded at the day of the challenge (a) or re-challenge (b). (a) Mean percentage of weight variation of animals inoculated
with SARS-CoV-2 Cat01 variant (blue) or with PBS mock solution (grey). P-value for statistically significant point: 2dpi p < .0001;
3dpi p = .0001; 4dpi p = .0002; 5 dpi p = .0003; 6dpi p < 0.0001; 7dpi p = .0005; 10dpi p = 0.0244. (b) Mean percentage of weight
variation of animals after SARS-CoV-2 re-inoculation. In blue animals exposed to SARS-CoV-2 Cat01 variant, in red animals exposed
to SARS-CoV-2 WA/1 variant, and in grey animals exposed to PBS mock.
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multifocally at 2 and 4 dpi. At 7 dpi, the same lesions
were observed but considered mild. Upon re-inocu-
lation, nasal turbinates showed mild lesions at
23 dpi, that is 2 days post-re-inoculation (2 dpri),
and dpi 25 (4 dpri), like those observed on 7 dpi.
The amount of SARS-CoV-2 nucleocapsid protein
(NP) detected by immunohistochemistry (IHC) in
nasal turbinates correlates with the intensity of lesions,
showing high, moderate and low amounts of viral
antigen at 2 dpi (Supplementary Figure 1 (Sp1) (a)),
4 dpi (Sp1(b)) and at 7 dpi (Sp1(c)) respectively.
Upon re-inoculation, the amount of labelling tended
to be mild-to-moderate at 23 dpi (2 dpri) (Sp1 (d,
e)) and very mild at 25 dpi (4 dpri) (Sp1(f, g)). Viral
antigen was mainly located in nasal epithelial cells,
including cells morphologically resembling olfactory
neurons and sloughed epithelial cells in the nasal mea-
tus, as well as submucosal gland cells.
Mild non-suppurative tracheitis with very mild pat-
chy loose of the respiratory epithelium cilia was
observed at 2 dpi; no evident lesions were observed
on the other days. All hamsters tested positive by
IHC at 2 dpi, and only two animals had very mild lab-
elling at 4 dpi. No immunohistochemical signal was
detected at 7 dpi or after re-inoculation with none of
the two SARS-CoV-2 isolates (Supplemental Figure 1).
At 2 dpi, all hamsters displayed mild to moderate
broncho-interstitial pneumonia (Figure 3(a)). At
4 dpi, lesions were moderate, including hyperplasia of
type II pneumocytes. Multifocal presence of fibrin
within alveoli containing inflammatory cells was also
observed (Figure 3(b)). Loss of cilia in affected respirat-
ory airways was evident. The same type of lesions but
more severe were observed at 7 dpi (Figure 3(c)). At 2
and 4 dpri lesions were equivalent to those described
at 4 dpi, being from very mild to moderate (Figure 3
(d, e)). Immunohistochemical labelling of SARS-
CoV-2 NP at 2 dpi varied from low to high and was
mainly observed in the bronchial and bronchiolar epi-
thelial cells and type I pneumocytes, following a patchy
distribution (mainly in peribronchial and peribronch-
iolar locations) (Figure 3(f)). At 4 dpi, SARS-CoV-2
NP protein distribution was similar to that at 2 dpi
but with a higher amount of labelling in the lung par-
enchyma and less in the bronchial and bronchiolar
epithelia. Noteworthy, type II pneumocytes and
mononuclear cells were scarcely labelled (Figure 3
(g)). Lungs tested positive at 7 dpi only in two animals.
In these samples, the number of labelled cells was very
scarce and was characterized by the presence of small
foci of type I pneumocytes containing viral antigen
(Figure 3(h)). All lung samples were negative at 2 and
4 dpri (respectively 23 and 25 dpi) (Figure 3(i,j)).
No histopathological findings were found in any of
the available mediastinal lymph nodes. By immuno-
histochemistry, the only available lymph nodes from
2 dpi (n = 1) and 4 dpi (n = 2), displayed low numbers
of dendritic-like cells (stellate appearance) containing
viral antigen in the cytoplasm (Supplementary
Figure 2). No labelling was detected in any of the med-
iastinal lymph nodes from hamsters at 7 dpi (n = 2), 2
dpri (n = 3) and 4 dpri (n = 4).
No apparent differences in lesion severity or immu-
nohistochemical labelling were observed for any tissue
upon re-inoculation with any of the two different
SARS-CoV-2 strains. A summary of the severity of
lesions and the amount of viral antigen per each individ-
ual hamster is displayed in the Supplementary Table 1.
A previous SARS-CoV-2 priming prevents re-
infection of the lower respiratory tract
We assessed viral genomic and subgenomic SARS-
CoV-2 RNA (gRNA and sgRNA, respectively) levels
in nasal turbinates, trachea, lungs and oropharyngeal
swabs at 2, 4, and 7 dpi (n = 4/day) and 2 and 4 dpri
(n = 3/day/viral variant) (Figure 4). In addition, we
analysed gRNA and sgRNA levels in oropharyngeal
swabs (OS) before the re-challenge to confirm that
animals cleared the infection.
After the first inoculation, SARS-CoV-2 gRNA
loads peaked at 2 dpi in all anatomical compartments
and then progressively decreased, accordingly to pre-
vious findings [18]. Viral loads in oropharyngeal
swabs were similar at 2 and 4 dpi but decreased by
7 dpi (Figure 4(a)). Upon re-inoculation, gRNA levels
of both viral strains were significantly lower in all
sample types in comparison to those obtained during
the first infection (Figure 4(a)). Only limited viral
gRNA levels were detected in trachea and lungs of
re-infected animals, regardless of the SARS-CoV-2
variant used. we detected higher gRNA levels in
Figure 3. Pathological findings in lungs of hamsters after inoculation and re-inoculation. (a–e) Histopathological findings in lungs
of hamsters after SARS-CoV-2 Cat01 challenge on 2 (a), 4 (b) and 7 (c) dpi, and 2 (d) and 4 (e) dpri with Cat01 and WA/1 variants.
Broncho-interstitial pneumonia (asterisks) severity increased from 2 to 7 dpi (maximum lesion severity) and was residual at 2 and 4
dpri. Inset in 2a displays submucosa mononuclear inflammation of the bronchus (asterisk) and exocytosis through the epithelium.
Hematoxylin and eosin stain, 100× magnification (inset in 2a, 400× magnification) (f to j). Immunohistochemical findings in lungs
of same animals. High amount of viral antigen (brown staining) mainly in bronchi epithelium as well moderate amount at 2 dpi (f,
inset shows a detail of the bronchus epithelial labelling). The maximum amount of labelling in lung parenchyma, associated with
the inflammatory infiltrate, was detected at 4 dpi (g). Scarce number of stained cells were detected at 7 dpi (h, arrowhead) and no
labelling was recorded at 2 (i) and 4 (j) dpri. Immunohistochemistry to detect the NP of SARS-CoV-2 and hematoxylin counterstain,
100× magnification (inset in 2a, 400× magnification). Scale bars, 100 μm.
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Cat01 (G614) re-infected nasal turbinates after 2 dpri
once compared to WA/1 (D614) infected samples.
This result is in accordance with recent studies [25]
and suggests an improved viral fitness conferred by
the G614 mutation in the upper airway of infected
hamsters.
To confirm whether gRNA detection correlated
with SARS-CoV-2 replication along the host cells,
we monitored the sgRNA levels, following a previously
described methodology [27,28] (Figure 4(b)). The
levels of SARS-CoV-2 sgRNA were lower than
gRNA levels in all hamster samples but also peaked
at 2 dpi and followed a similar declining trend over
time, as previously reported [13,28]. Detection of
sgRNA at 7 dpi was only possible in one nasal turbi-
nate and three out of four oropharyngeal swab
samples. Once the animals were re-inoculated,
sgRNA of both viral variants was detected in nasal tur-
binates at 2 and 4 dpri, but only at 2 dpri in OSs. We
did not detect sgRNA in trachea and lungs at any time
point post-re-inoculation, suggesting that both viral
strains were not able to successfully replicate in these
organs upon reinfection (Figure 4(b)).
Then, we compared the SARS-CoV-2 gRNA and
sgRNA loads obtained from the two infection events.
We found statistically significant reductions of both
genomic and subgenomic viral RNA levels in samples
of reinfected animals when compared to those
obtained after the first challenge; statistics are sum-
marized in Supplementary Table 2.
In addition to the molecular detection of gRNA and
sgRNA, the infectious viral titres were measured in
Vero E6 cells and expressed as TCID50/mL. We
detected infectious virus particles in all tissues and
OSs at 2 and 4 dpi; however, no infectious virus
samples were found from 7 dpi onwards (Figure 4
(c)). Infectious viral loads were particularly high in
nasal turbinates at 2 and 4 dpi. The lack of virus iso-
lation at 7 dpi samples (consistent with the low levels
of sgRNA and viral antigen detection) and the remis-
sion of clinical signs of animals (weight) starting from
5 dpi, indicate that these animals possibly cleared the
infection and stopped shedding infectious virus
around 7 dpi.
After re-challenge, at 2 dpri, we recorded the pres-
ence of infectious virus in two out of four nasal turbi-
nate samples of hamsters re-exposed to the Cat01
isolate. Similarly, only one animal inoculated with
the WA/1 variant displayed infectious virus in the
nasal turbinates. Re-infected positive animals were
much less susceptible to infection than those experi-
menting a first challenge (Figure 4(c)). Indeed, values’
variations obtained by quantifying genomic RNA,
subgenomic RNA or infectious viral particles were
statistically significant (Supplementary Table 2). Con-
versely, we were not able to identify infectious SARS-
CoV-2 particles from trachea, lungs or OSs of re-
inoculated hamsters at any time point, regardless of
the viral variant used.
Hamsters developed a neutralizing humoral
immune response against SARS-CoV-2 from 7
days post infection
To monitor humoral immune responses elicited by
golden Syrian hamsters upon infection with SARS-
CoV-2, we used the serum of individual hamsters col-
lected until 7 dpi and those generated during the re-
infection period (2 and 4 dpri). In addition, serum
was prepared from animals before the reinfection pro-
cedure (21 dpi) and pooled in groups of four (accord-
ing to animal caging at the BSL3 facility) to detect the
levels of the antigen-specific humoral response against
SARS-CoV-2. The levels of immunoglobulins target-
ing specific viral antigens encompassing the S protein
(S1+S2), the receptor binding domain (RBD) and the
NP were detected using an in house ELISA (Figure 5
(a–c)). Seroconversion against all tested proteins was
evident by 7 dpi, although S specific antibody levels
were notably lower than those against the RBD and
NP, probably due to a lower sensitivity of the S-
ELISA compared with the RBD one. Data obtained
from sera collected at 21 dpi suggested that total anti-
body levels targeting the S glycoprotein and those
recognizing specifically the RBD subdomain incre-
mented between 7 and 21 dpi. Conversely, the level
of NP-specific antibodies notably decreased at
21 dpi. After re-inoculation, the levels of antibodies
against S, RBD and NP antigens further increased
until 25 dpi (4 dpri) independently of the strain.
We then evaluated the neutralization activity of sera
obtained from all animals excepted those collected at
21 dpi. Neutralization activity was detected from 7 dpi
onwards, and sharply increased at 2 and 4 dpri (Figure
5(d,e)), similar to kinetic profiles of antigen-specific
antibodies detected by ELISA. Importantly, the
humoral response generated against the Cat01 strain
after the primary infection was able to neutralize
G614 and D614 viral isolates (Cat01 and WA/1,
respectively). Moreover, animals were protected from
reinfection at the lower respiratory tract against both
homologous and heterologous variants. Thus, the
high titre of neutralizing antibodies detected already
at 7 dpi (and onwards) might explain the partial protec-
tion (at the lower respiratory tract but not the upper
one) of these animals against the re-challenge, which
further caused a booster neutralizing effect.
Discussion
The golden Syrian hamster represents an animal model
able to recapitulate some infection/re-infection events
found in humans. Specifically, this model is character-
ized by mild-to-moderate clinical, pathological and
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Figure 4. Viral loads in samples obtained from hamsters after inoculation and re-inoculation with SARS-CoV-2. Genomic RNA (a)
and subgenomic RNA levels (b) of SARS-CoV-2 was analyzed in oropharyngeal swabs (OS), nasal turbinate, trachea, and lungs, as
well as the infectious viral loads (c). Horizontal bars reflect median viral loads. In blue data obtained from Cat01-reinfected animals,
in red data obtained from WA/1-reinfected animals. Dotted lines indicate the limit of detection for each technique. Statistically,
significant p values are reported in the graph, preceded by an (A) for ANOVA test or (K) for Kruskal–Wallis tests.
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virological outcomes upon infection with SARS-CoV-2,
and minimal virological outcome at the upper respirat-
ory tract upon reinfection with a D164-homologous or
a G614-heterologous SARS-CoV-2 variants.
Results obtained during the primary infection are
comparable to those reported in previous studies
[12,17,18], confirming the natural susceptibility of this
animal model to SARS-CoV-2. The golden Syrian
hamster reproduces the mild-to-moderate COVID-19
induced pathology described in humans, especially in
the lower respiratory tract [19]. Furthermore, we also
demonstrated for the first time that reinfection can
occur at the upper respiratory tract of this species
using either homologous or heterologous SARS-CoV-
2 variants. However, our results of virus titration,
gRNA and sgRNA detection indicate that negligible
or nil viral infection and replication occurred in the
lower respiratory tract of re-infected hamsters, regard-
less of the viral variant used. Conversely, both viral iso-
lates were able to infect nasal turbinates of animals
having resolved a primary infection. These results are
aligned with those described by van Doremalen et al.
[31], which showed that immune responses generated
by an adenovirus-vectorized ChAdOx1 vaccine, encod-
ing the spike protein of SARS-CoV-2, prevented viral
replication in the lower respiratory tract of challenged
rhesus macaques but not at the nasal turbinates. Impor-
tantly, no viral gRNA reduction was recorded in the
upper respiratory tract of non-human primates and
vaccinated animals shed high quantities of infectious
virus. Similarly, we found infectious SARS-CoV-2 par-
ticles in 1 or 2 out of 4 nasal turbinate samples of ham-
sters re-exposed to the SARS-CoV-2 WA/1 or CAT01
isolates, respectively. These results suggest that
human re-infections might also occur in the upper res-
piratory tract since a previously generated immunity is
not sterilizing at the nasal level.
Our study showed that infected animals developed
specific humoral immune responses against different
proteins of the SARS-CoV-2 from 7 dpi onwards. As
mentioned before, S and RBD specific antibodies
increased after 7 dpi. Conversely, levels of NP-specific
antibodies decreased until day 21 pi. In a recent study,
Chen et al. [32] analysed the IgG kinetic profile of
Figure 5. Humoral responses in SARS-CoV-2 reinfected hamster. (i) Antibody subclasses against (a) Spike protein subunits 1 and 2,
(b) receptor-binding domain (RBD) and (c) nucleocapsid protein. In black, serum samples from animals challenged with Cat01 (1st
inoculum), in blue serum from animals re-inoculated with the same viral variant (Cat01), in red serum from animal re-inoculated
with the different viral variant (WA/1). At 21 dpi before the re-inoculation sera were collected from Cat01-exposed animals, pooled
following housing criteria and analyzed (in gold). In grey, serum from control animals treated with a mock solution of PBS. (ii)
Serum from all animals was used for live virus neutralization assay against d) Cat01 and e) WA/1 variants. Code colour are the
same than those used in panel (i). Pooled sera were not tested in the SNT assay. Dotted lines indicate the limit of detection of
the technique.
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infected human patients, highlighting that SARS-CoV-2
infection induced a distinct temporal profile of humoral
responses against different viral proteins. These obser-
vations demonstrated that levels of NP-specific IgGs
tend to sharply decrease after 14–20 days post-symp-
toms in humans, similar to our observation in the
hamster model. Moreover, the virus neutralization
assay indicated that infected hamsters developed high
levels of SARS-CoV-2 neutralizing antibodies. Previous
studies in COVID-19 patients have correlated levels of
serological and mucosal neutralizing antibodies
[33,34], which have also been associated with infection
clearance. The same phenomenon could have occurred
in the golden Syrian hamster model after the primary
SARS-CoV-2 infection. These animals might have
mounted a strong mucosal and serological humoral
response able to neutralize the virus at the lower respir-
atory tract upon a secondary infection, as evidenced by
the high seroneutralizing antibody responses from
7 dpi onwards.This protective effectwas observed in tra-
chea and lungs independently of the viral variant used
for re-inoculation purposes. Remarkably, the immunity
developed by challenged hamsters was not sterilizing,
and localized infection at the upper respiratory tract
was still possible upon reinfection. However, animals
rapidly cleared the virus by day 4 dpri, similarly to
what was previously described in African Green mon-
keys [35] and Rhesus macaques [14] models.
In line with results obtained using the golden Syr-
ian hamster model, protection from a secondary infec-
tion was also described in rhesus macaques after two
consecutive SARS-CoV-2/WA1 inoculations [13].
Although low levels of viral replication were reported
in the nasal cavity of these non-human primates, dis-
ease prevention was also associated with the presence
of high neutralizing antibody levels in sera [13], a fact
that would also apply in the studied hamsters.
On the other hand, previous studies in human
patients have characterized T cell responses against
SARS-CoV and SARS-CoV-2 [36,37], demonstrating
the important role of the cellular components of
the immunity to resolve these Sarbecovirus infec-
tions. In addition, specific T cell responses generated
by the pre-exposition to seasonal human corona-
viruses (HCoV)-229E and OC43 or the zoonotic
SARS-CoV have been demonstrated to cross-react
and also target SARS-CoV-2 epitopes [38,39]. A
recent study from Brocato et al. [12] proved that dis-
ruption of lymphocytes in immunosuppressed
Golden Syrian hamsters severely affected the clinical
outcome of the SARS-CoV-2 infection, resulting in
an increased weight loss and higher viral loads
found in the lungs, and suggesting a critical role of
T-cells in the early phase of infection. The role of cel-
lular and mucosal immunity was not addressed in the
current work and, therefore, further studies would be
required to understand immune mechanisms
involved in the protection against SARS-CoV2
reinfection.
It was already known that seasonal HCoVs like
HKU1, OC43, or 229E can re-infect the same host
[40,41], suggesting a similar potential scenario for
SARS-CoV-2. In fact, several confirmed cases of
SARS-CoV-2 reinfection have been described world-
wide since mid-August 2020 [6–10.] To date, all rein-
fection cases were described by sequencing different
SARS-CoV-2 variants between the first and second epi-
sodes of infection. In the golden Syrian hamster model,
both homologous and heterologous variant reinfec-
tions were possible. Re-exposed animals did not show
evident clinical signs during the short phase of reinfec-
tion (2–4 days). Conversely, reinfections in humans
have been linked to different clinical outcomes. Symp-
tomatic reinfection ranged from more severe [7,9] to
milder forms [6,8]. Furthermore, asymptomatic rein-
fection has also been described [10]. This variability
might be the result of multiple factors as the overall
health condition of the patient, the initial viral load or
reinfection with a viral strain with higher replication
fitness and, importantly, the level of neutralizing anti-
bodies and specific T-cells at the time of subsequent
infection event. More studies are needed to establish
if different clinical outcomes are possible in case of
reinfection using the hamster model. This might be
obtained by modifying several aspects of the exper-
imental design as for example increasing the viral
load between challenges or using immunosuppressed
animals as suggested by Brocato et al. [12].
The overall frequency of reinfections in the human
population is difficult to establish, since a high number
of them could pass unnoticed. These could lead to
underestimate the rate of reinfection cases, especially
if the period between infections was particularly
short. In fact, a recent report highlighted that reinfec-
tion is possible within one month from the onset of
clinical symptoms [9]. Currently, the incidence rate of
reinfection is estimated to be approximately 0.36 per
10,000 person/week [11], which is rather significant
numerically, taking into account the high number of
new infection cases being reported daily [1]. Therefore,
massive testing and systematic monitoring of the popu-
lation that has been infected once would probably lead
to a much higher detection of reinfections than those
reported so far. In our study, the percentage of rein-
fected animals showing infectious virus in the upper
respiratory tract was notable: 1 out of 3 with animals
receiving the heterologous variant and 2 out of 3 that
were re-inoculated with the homologous variant.
These data emphasize the interest of the golden Syrian
hamster as a model to study reinfection mechanisms.
In summary, the golden Syrian hamster can be con-
sidered a convenient animal model to study reinfec-
tion pathogenesis and immune responses.
Specifically, this animal species can suffer from a
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clinical frame resembling mild-to-moderate disease in
humans, and reinfection with homologous (G614) or
heterologous (D614) variants yielded to a subclinical
infection of the upper respiratory tract. No sterilizing
immunity was elicited after the first infection event;
however, the lower respiratory tract was fully pro-
tected upon re-inoculation with both viral variants.
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